111 related articles for article (PubMed ID: 28125812)
1. Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Baek MH; Park JY; Rhim CC; Kim JH; Park Y; Kim KR; Nam JH
Gynecol Obstet Invest; 2017; 82(4):329-339. PubMed ID: 28125812
[TBL] [Abstract][Full Text] [Related]
2. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
Mitsuhashi T; Nakayama M; Sakurai S; Fujimura M; Shimizu Y; Ban S; Ogawa F; Hirose T; Ishihara O; Shimizu M
Ann Diagn Pathol; 2007 Feb; 11(1):49-54. PubMed ID: 17240308
[TBL] [Abstract][Full Text] [Related]
3. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
4. mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma.
Kerr DA; Busarla SVP; Gimbel DC; Sohani AR; Nazarian RM
Hum Pathol; 2017 Jul; 65():157-165. PubMed ID: 28506734
[TBL] [Abstract][Full Text] [Related]
5. Endometrial stromal sarcoma arising from endometriosis: a clinicopathological study and literature review.
Lan C; Huang X; Lin S; Cai M; Liu J
Gynecol Obstet Invest; 2012; 74(4):288-97. PubMed ID: 22986788
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.
Cossu-Rocca P; Contini M; Uras MG; Muroni MR; Pili F; Carru C; Bosincu L; Massarelli G; Nogales FF; De Miglio MR
Int J Gynecol Pathol; 2012 Nov; 31(6):570-9. PubMed ID: 23018215
[TBL] [Abstract][Full Text] [Related]
7. Oncogene alterations in endometrial carcinosarcomas.
Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
[TBL] [Abstract][Full Text] [Related]
8. Evolution in endometrial cancer: evidence from an immunohistochemical study.
Vandenput I; Trovik J; Leunen K; Wik E; Stefansson I; Akslen L; Moerman P; Vergote I; Salvesen H; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):316-22. PubMed ID: 21734474
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma.
Park JY; Kim KR; Nam JH
Int J Gynecol Cancer; 2013 Jan; 23(1):81-9. PubMed ID: 23221606
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Characterization of Histone Deacetylase as a Potential Prognostic Marker and Therapeutic Target in Endometrial Stromal Sarcoma.
Baek MH; Park JY; Rhim CC; Park Y; Kim KR; Kim JH; Nam JH
Anticancer Res; 2016 May; 36(5):2527-34. PubMed ID: 27127168
[TBL] [Abstract][Full Text] [Related]
12. Response to sunitinib malate in advanced alveolar soft part sarcoma.
Stacchiotti S; Tamborini E; Marrari A; Brich S; Rota SA; Orsenigo M; Crippa F; Morosi C; Gronchi A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2009 Feb; 15(3):1096-104. PubMed ID: 19188185
[TBL] [Abstract][Full Text] [Related]
13. Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
Quan P; Moinfar F; Kufferath I; Absenger M; Kueznik T; Denk H; Zatloukal K; Haybaeck J
Anticancer Res; 2014 Jun; 34(6):2883-97. PubMed ID: 24922651
[TBL] [Abstract][Full Text] [Related]
14. Endometrial stromal sarcoma: clinicopathological and immunophenotypic study of 16 cases.
Iwasaki S; Sudo T; Miwa M; Ukita M; Morimoto A; Tamada M; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Sakuma Y; Mikami Y; Nishimura R
Arch Gynecol Obstet; 2013 Aug; 288(2):385-91. PubMed ID: 23435725
[TBL] [Abstract][Full Text] [Related]
15. Expression of therapeutic targets in Ewing sarcoma family tumors.
Ahmed AA; Sherman AK; Pawel BR
Hum Pathol; 2012 Jul; 43(7):1077-83. PubMed ID: 22196127
[TBL] [Abstract][Full Text] [Related]
16. Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma.
Coosemans A; Van Calster B; Verbist G; Moerman P; Vergote I; Van Gool SW; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):302-8. PubMed ID: 21734473
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of endometrial stromal sarcoma and undifferentiated endometrial sarcoma as premises for new therapeutic strategies.
Hrzenjak A; Dieber-Rotheneder M; Moinfar F; Petru E; Zatloukal K
Cancer Lett; 2014 Nov; 354(1):21-7. PubMed ID: 25128649
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.
Kozakowski N; Hartmann C; Klingler HC; Susani M; Mazal PR; Scharrer A; Haitel A
Target Oncol; 2014 Dec; 9(4):359-66. PubMed ID: 24243494
[TBL] [Abstract][Full Text] [Related]
19. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
20. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
Adams SF; Hickson JA; Hutto JY; Montag AG; Lengyel E; Yamada SD
Gynecol Oncol; 2007 Mar; 104(3):524-8. PubMed ID: 17049587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
